Respiratory diseases arise from complex host–environment interactions driving structural and functional abnormalities across the airway epithelium and distal lungs. CELLnTEC delivers precision airway media and advanced in vitro cell culture systems to generate reproducible 2D and 3D respiratory models, including air-liquid interface (ALI) cultures, 3D ALI culture, organoids, and co-culture systems. These human-relevant platforms enable high-fidelity respiratory research, drug discovery, and translational respiratory models worldwide.
Chronic respiratory diseases such as asthma, COPD, fibrosis, and cystic fibrosis, together with viral infections including COVID-19, influenza, SARS-CoV-2, and rhinovirus, represent a major global health burden. Progress in respiratory disease modeling depends on advanced in vitro models that recapitulate the structure and function of the human airway epithelium from upper airways to distal lungs. CELLnTEC’s airway media support robust isolation, expansion, and differentiation of primary airway epithelial cells for consistent, physiologically relevant outcomes.
Engineered for nasal, tracheal, and bronchial epithelial cells, our airway portfolio enables standardized 2D and 3D air-liquid interface (ALI) culture workflows. These systems promote reliable epithelial maturation, mucociliary differentiation, and functional readouts essential for studying airway inflammation, lung remodeling, and chronic respiratory disease. Researchers can build translational respiratory models that closely reflect human airway biology and disease mechanisms.
CELLnTEC’s airway media support respiratory infection studies and viral pathogenesis research using human airway epithelial cells. Our in vitro respiratory models facilitate therapeutic screening of antivirals, biologics, and novel respiratory interventions against pandemic viruses. By strengthening human-relevant preclinical testing, we accelerate translational research and improve preparedness for emerging respiratory threats.
With an integrated workflow from biopsy to advanced translational respiratory models, CELLnTEC bridges discovery, drug discovery, and advanced therapy development. Our standardized airway cell culture systems enhance reproducibility, scalability, and regulatory readiness, supporting advanced therapy medicinal products (ATMPs), regenerative medicine, and precision medicine approaches in respiratory science.
CELLnTEC actively supports the 3R principle (Reduce, Replace, Refine) by enabling advanced in vitro respiratory models that minimize reliance on animal models. Our human airway epithelial platforms improve predictive validity while reducing animal experimentation in respiratory research and preclinical development. By advancing organoids, ALI cultures, and co-culture systems, we contribute to ethical science and accelerate ATMP development with clinically translatable human data.
Supports large airway epithelial cells and is compatible with airway, bronchial, nasal, and lung epithelial models.
Chemically defined, animal- and human-component-free media for highly reproducible respiratory models.
Supports multi-tissue workflows with alveolar and lung fibroblasts.
Backed by Swiss-quality manufacturing, technical documentation, and responsive scientific support.
3D ALI cultures and scaffold-based lung models that recapitulate upper, lower, and distal airway regions for infection and antiviral drug testing.
Airway wound repair, migration, and matrix remodeling assays in COPD, cystic fibrosis, and chronic airway disease.
Responsive models for functional readouts such as ciliary beating, mucus production, and barrier integrity.
Evaluating the host–pathogen interaction of SARS-CoV-2, pandemic influenza, rhinovirus, and other clinically relevant pathogens.
Advanced models for toxicology, aerosol delivery, and environmental exposure testing.
1
Ready-to-use defined media reduces variability, simplifies culture handling, and shortens time-to-data in complex respiratory projects.
3
Optimized media and protocols create infection-compatible airway models that sustain virus replication while preserving epithelial differentiation and barrier function.
2
Optimized media and protocols specifically designed to deliver the delicate balance to retain the basal layer, but in parallel to allow more complete differentiation.
4
Clinically-ready formulation aligns respiratory workflows with regulatory expectations and clinical development prerequisites.
Primary epithelial cells growing in CnT-NX-EX display a highly proliferative phenotype. For differentiation experiments, it is recommended to switch to the CnT-PR-D or CnT-PR-3D differentiation media.
